FIELD: medicine; veterinary medicine.
SUBSTANCE: invention relates to the immunotherapy of malignant neoplasms using genetically modified lymphokine-activated killer cells (LAK cells) with a universal chimeric antigen T-cell receptor. The invention is CAR-LAK cells biomedical cell product with a universal T-cell receptor (CD16-CAR) characterized by CAR+CD25+CD3+ and CAR+CD16+CD56+ phenotype. The biomedical cell product is intended for the treatment of cancer patients in combination with monoclonal antibodies to tumour antigens.
EFFECT: invention makes it possible to obtain a biomedical cell product with antitumor activity regulated by monoclonal antibodies.
1 cl, 1 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIOMEDICAL CELL PRODUCT WITH ANTI-HER2 SPECIFIC ANTI-TUMOUR ACTIVITY | 2019 |
|
RU2728361C1 |
| BIOMEDICAL CELL PRODUCT WITH SPECIFIC ANTITUMOR ACTIVITY, REPRESENTED BY POPULATIONS OF LYMPHOKINE-ACTIVATED KILLERS AND ANTI-HER2 CAR-γδΤ-OIL AND ANTI-HER2 CAR-T-NK | 2022 |
|
RU2786210C1 |
| PSCA-CAR-YT CELL LINE HAVING SURFACE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND EXHIBITING CYTOTOXIC ACTIVITY ON PSCA-POSITIVE HUMAN CANCER CELLS | 2018 |
|
RU2712901C1 |
| BIODEGRADABLE IMPLANT FOR LOCAL IMMUNOTHERAPY OF CANCER PATIENTS | 2021 |
|
RU2780932C1 |
| BIODEGRADABLE METAL IMPLANT FOR LOCAL IMMUNOTHERAPY OF PATIENTS WITH SOLID TUMORS | 2021 |
|
RU2780927C1 |
| METHOD FOR PRODUCING ANTI-TUMOR IMMUNOLOGICAL PROTECTION TO EL-4 LYMPHOMA CELLS | 2018 |
|
RU2708558C1 |
| TITANIUM IMPLANT WITH THE FUNCTION OF LOCAL IMMUNOTHERAPY FOR OSTEORECONSTRUCTIVE SURGERY AND PREVENTION OF LOCAL RECURRENCE OF ONCOLOGICAL DISEASE AND METHOD FOR ITS MANUFACTURE | 2021 |
|
RU2779367C1 |
| METHOD FOR DETERMINING MINIMAL RESIDUAL DISEASE BY MULTIPARAMETER FLOW CYTOMETRY IN CHILDREN AND ADULTS WITH B-LINEAR ACUTE LYMPHOBLASTIC LEUKEMIA IN CONDITIONS OF CD19-DIRECTED IMMUNOTHERAPY | 2022 |
|
RU2818950C1 |
| INSERTION OF TARGET GENE FOR IMPROVED CELLULAR IMMUNOTHERAPY | 2017 |
|
RU2824204C2 |
| METHOD FOR CREATION OF T-CELLS SUITABLE FOR ALLOGENEIC TRANSPLANTATION | 2015 |
|
RU2752933C2 |
